Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/531"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:Evidence_value | |
| ?:content |
"route of admininistration: oral
study duration: 6 days
population: 16 healthy subjects (8 male, 8 female) from the UK; 15 Caucasian, 1 of African ancestry
tested for known CYP450 polymorphisms?
Yes -- CYP2D6 and CYP2C19 genotyping -- 1 CYP2D6 poor metabolizer
ages: 18-45
description:
SUBJECTS: 16 healthy subjects (18-45 years; eight male and eight female (15 Caucasian and one black subject) in the omeprazole study were recruited in the UK. CYP2D6 and CYP2C19 [genotyping] were determined according to standard methods. The results were only used to aid interpretation of the pharmacokinetic results.
STUDY DESIGN: Sixteen subjects were administered omeprazole (30 mg once daily) or placebo for 6 days. On the morning of day 5, a single dose of 20 mg escitalopram was administered. The wash-out period was 3 weeks between the treatments.
RESULTS: Omeprazole (30 mg once daily) caused a significant increase (+51%) in the AUC(0-inf) for escitalopram given as a single 20 mg oral dose.
A single CYP2D6 poor metabolizer was identified in each of the two studies. However, the results from these subjects were within the ranges of those from the other subjects."
|
| dc:creator | |
| dc:date |
"09/15/2010 13:07:44"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ omeprazole_increases_auc_escitalopram, <http://purl.org/swan/1.2/swan-commons#citesAsSupportingEvidence>, evidence_1768 }